介质细胞干细胞治疗在多发性硬化症中的免疫调节作用:系统性审查
Maysaa N Amin1, Rahma Hashish2, Khaled Agha Tabari3
1Microbiology and Immunology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus
|July 30, 2025
概括
介质干细胞 (MSC) 疗法通过改善免疫平衡和减少神经炎症,对多发性硬化症 (MS) 显示出前景. 这种疗法似乎是安全有效的,具有个性化MS治疗的潜力.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 再生医学是一种再生医学.
背景情况:
- 多发性硬化症 (MS) 是一种渐进的免疫媒介疾病,导致髓降解,炎症和神经退行.
- 介质干细胞 (MSC) 疗法正在MS治疗中被研究其神经保护和免疫调节潜力.
研究的目的:
- 系统地审查MSC移植对脑脊液 (CSF) 生物标志物和MS患者免疫系统的影响.
- 使用PRISMA指南评估MSC治疗多发性硬化症的安全性和有效性.
主要方法:
- 按照PRISMA指南进行了系统审查.
- 包括的研究包括RCT,非随机实验研究,系统性审查与元分析,以及叙述性审查.
- 分析的重点是脑脊液生物标志物,免疫细胞群 (Tregs,Th17) 和临床结果 (EDSS,MRI病变) 的变化.
主要成果:
- MSC治疗导致神经保护性CSF生物标志物的显著积极变化.
- 在免疫学上,MSCs促进了调节性T细胞 (Treg) 扩张,并抑制了T辅助型17 (Th17) 活动,减少神经炎症.
- 从临床上看,一组患者在扩展残疾状态量表 (EDSS) 得分上有所改善,并减少了MRI损伤负担.
- MSC治疗通常是安全的,有轻微的,自我限制的副作用.
结论:
- 基于MSC的疗法在治疗多发性硬化症方面具有显著的潜力.
- 该疗法在恢复免疫平衡和提供神经保护方面表现有前途.
- 需要进一步的研究来解决研究设计中的异质性,以提高可比性和个性化MS管理.
更多相关视频
07:45Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases
Published on: September 1, 2017
12.2K
04:53Author Spotlight: Advancing Treatment Approaches with Adipose-Derived Stem Cells
Published on: January 12, 2024
1.0K
相关概念视频
Mesenchymal Stem Cells
5.0K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.0K
Stem Cell Therapy for Tissue Regeneration
4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Multipotency of Hematopoietic Stem Cells
3.3K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.3K
Regulation of Hematopoietic Stem Cells
3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
